Virtual Library
Start Your Search
FLAVIA Ejzykowicz
Author of
-
+
EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.16-04 - Real World Clinical Outcomes for Metastatic Non-Small Cell Lung Cancer (mNSCLC) at IRST Italy (Now Available) (ID 2307)
08:00 - 18:00 | Author(s): FLAVIA Ejzykowicz
- Abstract
Background
This study sought to evaluate the real word clinical outcomes concerning overall survival (OS) for patients in first-line treatment for metastatic non-small cell lung cancer (mNSCLC) prior to the availability of immunotherapies in any line.
Method
Patients who received systemic anti-cancer treatment for mNSCLC at IRST between Jan2014-Jun2017 with a minimum follow-up of six months were included. The clinical dataset was obtained from data registered in electronic health records maintained during clinical practice. OS was defined as the interval from start of first-line therapy until death or follow-up end, whichever occurred first. Death information was detected from mortality register. OS was estimated using the Kaplan-Meier method stratified by type of first-line treatment.
Result
Among the 428 first-line patients analyzed, 64.5% were over 65 years old and 62.6% were men (Table 1). A total of 79.0% patients had non-squamous histology whereas 15.0% had squamous histology, with the remaining 6% other histologies. EGFR mutation was detected in 15.7% and ALK translocation in 8.4% of patients. In the first-line the majority (57.0%) of patients received platinum-doublet (mainly platinum+pemetrexed) while single agent chemotherapy was administered in 23.8%, whereas 10.0% received targeted therapy. Conversely overall 9.0% were enrolled in clinical trials, while 0.2% received Immunotherapies. Median OS was 19.9 months (95%CI:9.2-21.7) with targeted therapy, 8.5 months (95%CI:4.8-13.6) for patients enrolled in clinical trials, 6.4 months (95%CI:5.8-7.6) with platinum-doublet and 4.4 months (95%CI:3.7-5.7) with single agent chemotherapy. A total of 34.5% of first-line patients continued to receive second-line treatment.
Conclusion
In this analysis prior to the introduction of immunotherapies for NSCLC, OS was similar to real world OS in the published literature. The survival was worse in the single agent chemotherapy group while it is superior in platinum doublets group. Overall survival was longest in patients treated with targeted therapy.
-
+
P2.01 - Advanced NSCLC (ID 159)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.01-54 - Real-World PD-L1 Testing Patterns for Patients with Advanced Non-Small Cell Lung Cancer in Greece (ID 2138)
10:15 - 18:15 | Author(s): FLAVIA Ejzykowicz
- Abstract
Background
Programmed Cell Death Protein-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors are important immunotherapy targets for non-small cell lung cancer (NSCLC). This study sought to describe PD-L1 testing for patients with NSCLC in Greece.
Method
This non-interventional study is based on Sotiria Lung Cancer Registry in Greece recording patients with histologically or cytologically confirmed stage IIIB/IV NSCLC diagnosis, who initiated systemic treatment between August, 15th 2016 and August, 14th 2018.
Result
A total of 472 patients were included in the registry. Demographic and first-line treatment information are presented in Table 1, along with the respective comparison between patients tested and not tested for PD-L1. Patients with ECOG PS 0-1 are more likely to be tested for PD-L1 status. Among patients tested for PD-L1, Dako 22C3 was the most commonly used testing assay (87.8%).
The number of patients tested for PD-L1 increased between the two consecutive time periods (from August, 15th 2016 to August, 14th 2018; Table 2).
Conclusion
The percentage of newly diagnosed patients with advanced NSCLC in Greece tested for PD-L1 status doubled in a year (August, 15th 2016 – August, 14th 2018). Among those tested, 67% were tested prior to first-line treatment initiation and 26% of those tested had PD-L1 TPS ≥50%.
